13.05.2013 - Norwegian targeted radio-cancer therapy specialist Algeta ASA (Oslo) has added Hilde Furberg as Non-executive Director to its board.
The nuclear chemist has 30 years of experience in the pharmaceutical industry. Furberg is currently Senior VP Rare Disease EMEA at Genzyme (now Sanofi). Prior to Genzyme, she spent 15 years at Baxter. She is a Non-executive Director on the Board of Clavis Pharma ASA, and is also a board member at Copenhagen Capacity. Her previous board memberships include Probi AB and Pronova Biopharma ASA (until its acquisition by BASF).http://www.european-biotechnology-news.com/people/bio-people/2013-01/hilde-furberg.html